Peptides for Weight Loss: What the Research Shows

Weight loss is arguably the most clinically advanced area of peptide therapeutics. While many peptide categories rely entirely on animal data, the weight management space has FDA-approved drugs backed by some of the largest clinical trials in recent pharmaceutical history.

This guide covers the peptides most commonly discussed for weight management, organized by strength of evidence. The differences are stark — some compounds have data from trials involving thousands of participants, while others have essentially no human evidence at all.

A critical distinction: FDA-approved peptide drugs (semaglutide, tirzepatide) are prescribed by physicians and have well-characterized safety profiles. Research peptides discussed for weight loss (AOD-9604, MOTS-c) do not have this level of evidence and are not approved for human use.

Semaglutide is a GLP-1 receptor agonist and the most extensively studied peptide for weight management. It mimics the natural incretin hormone GLP-1, which regulates appetite, insulin secretion, and gastric emptying.

Key clinical evidence: The STEP trial program (Semaglutide Treatment Effect in People with Obesity) is a series of large RCTs. STEP 1 (n=1,961) demonstrated 14.9% mean body weight reduction with semaglutide 2.4mg weekly versus 2.4% with placebo over 68 weeks. 86.4% of participants achieved at least 5% weight loss (Wilding et al., 2021; PMID: 33567185).

The SELECT trial (n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese adults with cardiovascular disease, leading to an expanded FDA indication for cardiovascular risk reduction in 2024.

FDA status: Approved. Ozempic (lower dose) for type 2 diabetes. Wegovy (2.4mg) for chronic weight management. Rybelsus for oral administration.

Common side effects: Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), primarily during dose escalation. Most gastrointestinal effects decrease over time.

Read our full semaglutide compound page for complete research details.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two incretin receptors simultaneously, which appears to produce greater weight loss than GLP-1 agonism alone.

Key clinical evidence: The SURMOUNT-1 trial (n=2,539) demonstrated mean weight loss of 22.5% with the highest dose (15mg weekly) versus 2.4% with placebo over 72 weeks. 63% of participants on the 15mg dose achieved at least 20% weight loss, and 36% achieved at least 25% weight loss (Jastreboff et al., 2022; PMID: 35658024).

These results represent the highest weight loss achieved by any approved medication to date. The magnitude approaches what was previously only achievable with bariatric surgery.

FDA status: Approved. Mounjaro for type 2 diabetes (2022). Zepbound for chronic weight management (2023).

Common side effects: Similar to semaglutide — nausea, diarrhea, vomiting, constipation. Gastrointestinal effects are the primary adverse events.

Read our full tirzepatide compound page for complete research details.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It represents the next generation of incretin-based therapies and is currently in Phase 3 clinical trials.

Key clinical evidence: A Phase 2 trial (n=338) showed mean weight loss of 24.2% at the highest dose over 48 weeks. Participants who continued the highest dose for an additional 24 weeks showed continued weight loss, suggesting the plateau may not have been reached at 48 weeks (Jastreboff et al., 2023; PMID: 37385275).

If Phase 3 results confirm these findings, retatrutide could surpass tirzepatide as the most effective weight management peptide. However, Phase 2 results do not always replicate in larger Phase 3 trials.

FDA status: Not approved. Phase 3 trials ongoing. Developed by Eli Lilly.

Read our full retatrutide compound page for more details.

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that was studied for fat metabolism effects without the growth-promoting properties of full-length GH.

Key evidence: Early studies suggested AOD-9604 could stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat creation) in animal models. However, a Phase 2b clinical trial for obesity did not demonstrate statistically significant weight loss compared to placebo. The compound was not advanced to Phase 3.

Despite the failed clinical trial, AOD-9604 remains popular in online peptide communities. It is sometimes marketed by compounding pharmacies and peptide vendors, often based on the preclinical data while omitting the negative clinical trial result.

FDA status: Not approved. Not actively in clinical development for weight loss. The TGA (Australia) has approved it as a food supplement ingredient.

The contrast between AOD-9604 and the GLP-1 drugs illustrates why evidence quality matters. AOD-9604 has animal data suggesting fat metabolism effects, but when tested in humans in a controlled trial, it did not outperform placebo. Meanwhile, semaglutide and tirzepatide have replicated their results across multiple large trials.

Here is how the major weight loss peptides compare on key metrics:

Semaglutide has strong evidence, FDA approval, demonstrated 14.9% weight loss in STEP 1, and costs approximately $1,000-1,350 per month at retail price.

Tirzepatide has strong evidence, FDA approval, demonstrated 22.5% weight loss in SURMOUNT-1, and costs approximately $1,000-1,100 per month.

Retatrutide has moderate evidence (Phase 2 only), is not yet approved, demonstrated 24.2% in Phase 2, and is not commercially available yet.

AOD-9604 has preliminary evidence, is not approved, failed to show significant results in its Phase 2b human trial, and varies in cost from unregulated sources.

For a detailed interactive comparison, visit our comparison tool.